Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 9, 2007. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the Company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of specific share transactions rather than a financial performance report.
Material Changes and Transactions
The filing details three specific transactions executed on January 8, 2007, involving the GlaxoSmithKline Employee Trust ("the GSK Trust"):
- Transfer of 10,800 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991.
- Sale of 1,565 Ordinary Shares on behalf of participants in the GlaxoSmithKline Share Value Plan at a price of GBP 13.72 per share.
- Transfer of 4,135 Ordinary Shares to participants in the GlaxoSmithKline Share Value Plan.
Three directors (Dr J-P Garnier, Dr M M Slaoui, and Mr J S Heslop) are noted as having an interest in shares held within the GSK Trust in the same capacity as other employees.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is strictly a notification of share movements under Disclosure Rule 3.1.4R(1)(b).
Investor Verification Points
- Verify the total number of shares transferred or sold by the GSK Trust on January 8, 2007 (Total: 16,500 shares).
- Confirm the transaction price of GBP 13.72 per share for the Share Value Plan sales.
- Review the specific roles of the three directors mentioned to understand their indirect interest in the trust holdings.